- VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
- The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
- VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
- The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats.
- VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results provide initial evidence supporting the company’s approach of using dual-targeted mechanisms to activate potent therapeutic payloads only when both components reach the same tumor cell.
Traditional antibody-drug conjugates have transformed parts of cancer treatment by allowing targeted delivery of highly potent therapies. However, a continuing challenge within the field is the unintended exposure of healthy tissue to toxic payloads, which can limit dosing and contribute to adverse effects.
VERAXA’s BiTAC strategy, short for Bi-targeted Tumor-Associated Cytotoxicity, seeks to address this challenge by separating a therapeutic system into two complementary molecules. Individually, these molecules are designed to remain inactive. Therapeutic activity occurs only when both components bind to the intended cancer cell, creating an “AND-gated” approach aimed at improving tumor specificity.
According to the company, this architecture is being applied across two major technology platforms: BiTAC-ADCs and BiTAC-TCEs. The BiTAC-TCE platform was previously presented at the American Association for Cancer Research (“AACR”) Annual Meeting in 2026, where early preclinical data showed selective activity against cells expressing both target markers while reducing effects on cells carrying only one of the targets. Together, the BiTAC-ADC and BiTAC-TCE programs represent VERAXA’s strategy of developing conditionally activated therapies that may offer a broader therapeutic window compared with conventional approaches.
The company entered the public markets in June 2026 following the completion of its business combination with Voyager Acquisition Corp., beginning trading on the NASDAQ Capital Market under the ticker symbol VRXA. The listing provides VERAXA with greater access to capital markets as it advances its pipeline and evaluates future collaboration opportunities.
Beyond its BiTAC programs, VERAXA is developing a broader portfolio of antibody-based therapeutics focused on oncology. The company’s pipeline includes additional mono- and bispecific ADC programs, and other engineered therapeutic formats.
Its most advanced clinical-stage program, VX-A901, is a monoclonal antibody targeting FLT3 for the treatment of acute myeloid leukemia (“AML”). The therapy is designed to stimulate antibody-dependent cellular cytotoxicity, helping immune cells recognize and attack cancer cells. Early Phase I data indicated that the treatment was well tolerated among heavily pre-treated AML patients and showed initial signs of anti-tumor activity. As VERAXA increases its emphasis on solid tumor applications and BiTAC-based modalities, it intends to seek partners for the future development and commercialization of VX-A901.
The company’s research strategy reflects broader trends within the oncology industry, where pharmaceutical developers are increasingly investing in therapies that can improve targeting precision and reduce damage to healthy tissue. ADCs and bispecific antibodies have become important areas of research because they combine the specificity of antibodies with powerful therapeutics.
Market forecasts indicate substantial growth opportunities in these sectors. According to Grand View Research, the global antibody-drug conjugates market was valued at approximately $12.26 billion in 2024 and is expected to reach about $32.11 billion by 2033, driven by increasing demand for targeted cancer treatments (https://nnw.fm/B4Nv8). The market for bispecific antibodies is also projected to expand significantly over the next decade, supported by continued advances in immuno-oncology and precision medicine.
VERAXA traces its scientific origins to discoveries made at the European Molecular Biology Laboratory (“EMBL”), a research institution recognized for contributions to molecular biology and biotechnology. The company has built its development platform around proprietary antibody engineering technologies, biorthogonal click chemistry, and tumor-selective activation strategies designed to create more precise cancer therapeutics.
For more information, visit the company’s website at www.Veraxa.com.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
